WOCKPHARMA vs ZIMLAB: Stock Comparison

Wockhardt Ltd vs Zim Laboratories Limited

Live data: 22 July 2026, 3:02 PM IST • Source: NSE and company filings

Wockhardt Ltd is the larger company by market capitalisation. Wockhardt Ltd shows a higher ROE, faster revenue growth and a higher net margin, while Zim Laboratories Limited shows a lower P/E, a higher dividend yield and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Wockhardt Ltd and Zim Laboratories Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, WOCKPHARMA is more favourable on 8 of 13 scored metrics and ZIMLAB on 5These counts are context-free and are not an overall rating.

Key Differences

Market Cap
WOCKPHARMA is the larger company
₹30,362 Cr vs ₹656 Cr
P/E Ratio
ZIMLAB has a lower P/E
112.39x vs 144.46x
P/B Ratio
ZIMLAB has a lower P/B
2.21x vs 6.23x
EPS
WOCKPHARMA has higher earnings per share
₹13.1 vs ₹1.94
Dividend Yield
ZIMLAB has a higher dividend yield
0.02% vs 0%
Revenue Growth (TTM YoY)
WOCKPHARMA has faster revenue growth
26% vs -3.36%
EPS Growth (TTM YoY)
WOCKPHARMA has faster EPS growth
0% vs -47.01%
Qtr Sales Growth
WOCKPHARMA has stronger quarterly sales growth
29.9% vs -12.3%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricWOCKPHARMAZIMLAB
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricWOCKPHARMAZIMLAB
Live Price₹1,865.9₹104.91
Day Change-1.6%0.25%
Volume7.19 L81,241
52-Week High₹2,422.3₹121.47
52-Week Low₹1,086.7₹59.31
Distance from 52W High-22.97%-13.63%

Valuation

MetricWOCKPHARMAZIMLAB
Market Cap₹30,362 Cr₹656 Cr
P/E Ratio144.46x112.39x
P/B Ratio6.23x2.21x
EPS₹13.1₹1.94
Book Value₹304₹51.77
Dividend Yield0%0.02%

Growth

MetricWOCKPHARMAZIMLAB
Revenue Growth (TTM YoY)26%-3.36%
EPS Growth (TTM YoY)0%-47.01%
Qtr Sales Growth29.9%-12.3%
Qtr Profit Growth688%-308%

Profitability & Leverage

MetricWOCKPHARMAZIMLAB
ROE6.11%1.97%
ROCE7.55%8.16%
Net Margin3.3%1.56%
Operating Margin19.3%5.72%
Debt to Equity0.45x0.42x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricWOCKPHARMAZIMLAB
Promoter Holding49.08%30.36% 0.01 pp
FII Holding7.09% 0.1 pp0.03% 0.03 pp
DII Holding10.96% 0.41 pp1.33% 1.26 pp
Public Holding32.83% 0.52 pp68.28% 1.3 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Wockhardt Ltd and Zim Laboratories Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.